Loading
A phase 2 trial of Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm is a phase 2 interventional study registered as NCT05546866 by AstraZeneca, with 51 participants enrolled, started 2023-02-09 and due to reach its primary completion in 2029-06-30. Interventions recorded: Osimertinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Osimertinib, Resectable stage I to III non-small-cell lung cancer, AstraZeneca, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, Resectable stage I to III non-small-cell lung cancer, AstraZeneca, Small-cell lung cancer.
Shares Osimertinib, Resectable stage I to III non-small-cell lung cancer, AstraZeneca, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Resectable stage I to III non-small-cell lung cancer, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.